The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fowler, D. H.
Right arrow Articles by Gress, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fowler, D. H.
Right arrow Articles by Gress, R. E.

The Journal of Immunology, Vol 157, Issue 11 4811-4821, Copyright © 1996 by American Association of Immunologists

ARTICLES

Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease

DH Fowler, J Breglio, G Nagel, MA Eckhaus and RE Gress
Transplantation Therapy Section, Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Allogeneic CD8+ T cells mediate both a graft-vs-leukemia (GVL) effect and graft-vs-host disease (GVHD). To evaluate whether CD8 cells of defined cytokine phenotype differentially mediate these processes, alloreactive donor CD8+ T cells preferentially secreting type I or type II cytokines were generated by alloantigenic priming in vitro in the presence of IL-12 or IL-4, respectively. Both cytokine-secreting subsets lysed allogeneic tumor targets in vitro ("Tc1" and "Tc2" subsets). A transplantation model was established (B6 into B6C3F1, 1050 cGy host irradiation) using the 32Dp210 myeloid line (bcr/abl transfected, H-2k; 1 x 10(4) tumor cells/recipient). Compared with leukemia controls (death at 12.9 days post-bone marrow transplantation), both Tc1 and Tc2 recipients were conferred a survival advantage. At cell doses of 2 to 2.5 x 10(7), the Tc1-mediated GVL effect (mean survival of 34.2 days) was more potent than the Tc2- mediated GVL effect (mean survival of 20.5 days; Tc1 > Tc2, p = 0.009). On day 15, histologic examination showed that Tc1 recipients had undetectable tumor burdens, whereas Tc2 recipients had extensive leukemic infiltrates. However, Tc2 recipients had essentially no histologic evidence of GVHD, whereas Tc1 recipients had mild to moderate GVHD (average GVHD scores of 1/40 and 9.3/40, respectively). In contrast, recipients of uncultured CD8+ donor T cells developed severe GVHD (average GVHD score of 26.7/40). Because in vitro- generated, alloreactive Tc1 and Tc2 populations mediated GVL with reduced GVHD, we conclude that both subsets may improve the therapeutic outcome of allogeneic T cell transfers in patients with leukemia.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Zhang, J. Lou, N. Li, I. Todorov, C.-L. Lin, Y.-A. Cao, C. H. Contag, F. Kandeel, S. Forman, and D. Zeng
Donor CD8+ T Cells Mediate Graft-versus-Leukemia Activity without Clinical Signs of Graft-versus-Host Disease in Recipients Conditioned with Anti-CD3 Monoclonal Antibody
J. Immunol., January 15, 2007; 178(2): 838 - 850.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Uss, A. T. Rowshani, B. Hooibrink, N. M. Lardy, R. A. W. van Lier, and I. J. M. ten Berge
CD103 Is a Marker for Alloantigen-Induced Regulatory CD8+ T Cells.
J. Immunol., September 1, 2006; 177(5): 2775 - 2783.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. E. Foley, U. Jung, A. Miera, T. Borenstein, J. Mariotti, M. Eckhaus, B. E. Bierer, and D. H. Fowler
Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism
J. Immunol., November 1, 2005; 175(9): 5732 - 5743.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
Y. REISNER, H. GUR, S. REICH-ZELIGER, M. F. MARTELLI, and E. BACHAR-LUSTIG
Hematopoietic Stem Cell Transplantation across Major Genetic Barriers: Tolerance Induction by Megadose CD34 Cells and Other Veto Cells
Ann. N.Y. Acad. Sci., June 1, 2005; 1044(1): 70 - 83.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. W. Blaser, S. Roychowdhury, D. J. Kim, N. R. Schwind, D. Bhatt, W. Yuan, D. F. Kusewitt, A. K. Ferketich, M. A. Caligiuri, and M. Guimond
Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease
Blood, January 15, 2005; 105(2): 894 - 901.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Reich-Zeliger, E. Bachar-Lustig, J. Gan, and Y. Reisner
Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. I. Relative Reactivity of Different Veto Cells
J. Immunol., December 1, 2004; 173(11): 6654 - 6659.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Xystrakis, A. S. Dejean, I. Bernard, P. Druet, R. Liblau, D. Gonzalez-Dunia, and A. Saoudi
Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation
Blood, November 15, 2004; 104(10): 3294 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Xystrakis, P. Cavailles, A. S. Dejean, B. Cautain, C. Colacios, D. Lagrange, M.-J. van de Gaar, I. Bernard, D. Gonzalez-Dunia, J. Damoiseaux, et al.
Functional and Genetic Analysis of Two CD8 T Cell Subsets Defined by the Level of CD45RC Expression in the Rat
J. Immunol., September 1, 2004; 173(5): 3140 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing
Blood, June 1, 2004; 103(11): 4353 - 4361.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Young, L. S. Kay, M. J. Phillips, and L. Zhang
Antitumor Activity Mediated by Double-Negative T Cells
Cancer Res., November 15, 2003; 63(22): 8014 - 8021.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
U. Jung, J. E. Foley, A. A. Erdmann, M. A. Eckhaus, and D. H. Fowler
CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects
Blood, November 1, 2003; 102(9): 3439 - 3446.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Bachar-Lustig, S. Reich-Zeliger, and Y. Reisner
Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose
Blood, September 15, 2003; 102(6): 1943 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. J. Young, B. DuTemple, M. J. Phillips, and L. Zhang
Inhibition of Graft-Versus-Host Disease by Double-Negative Regulatory T Cells
J. Immunol., July 1, 2003; 171(1): 134 - 141.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation
Blood, February 15, 2003; 101(4): 1290 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
F. Lenfant, N. Pizzato, S. Liang, C. Davrinche, P. Le Bouteiller, and A. Horuzsko
Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice
J. Gen. Virol., January 1, 2003; 84(2): 307 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Lavenu-Bombled, C. D. Trainor, I. Makeh, P.-H. Romeo, and I. Max-Audit
Interleukin-13 Gene Expression Is Regulated by GATA-3 in T Cells. ROLE OF A CRITICAL ASSOCIATION OF A GATA AND TWO GATG MOTIFS
J. Biol. Chem., May 17, 2002; 277(21): 18313 - 18321.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Zeng, P. Hoffmann, F. Lan, P. Huie, J. Higgins, and S. Strober
Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation
Blood, February 15, 2002; 99(4): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. Reynolds, V. A. Norgan, U. Bhambra, J. Smith, H. T. Cook, and C. D. Pusey
Anti-CD8 Monoclonal Antibody Therapy Is Effective in the Prevention and Treatment of Experimental Autoimmune Glomerulonephritis
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 359 - 369.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
O. Alpdogan, C. Schmaltz, S. J. Muriglan, B. J. Kappel, M.-A. Perales, J. A. Rotolo, J. A. Halm, B. E. Rich, and M. R. M. van den Brink
Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease
Blood, October 1, 2001; 98(7): 2256 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Chtanova, R. A. Kemp, A. P. R. Sutherland, F. Ronchese, and C. R. Mackay
Gene Microarrays Reveal Extensive Differential Gene Expression in Both CD4+ and CD8+ Type 1 and Type 2 T Cells
J. Immunol., September 15, 2001; 167(6): 3057 - 3063.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Role of Effector Cell-Derived IL-4, IL-5, and Perforin in Early and Late Stages of Type 2 CD8 Effector Cell-Mediated Tumor Rejection
J. Immunol., July 1, 2001; 167(1): 424 - 434.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Schmaltz, O. Alpdogan, K. J. Horndasch, S. J. Muriglan, B. J. Kappel, T. Teshima, J. L. M. Ferrara, S. J. Burakoff, and M. R. M. van den Brink
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
Blood, May 1, 2001; 97(9): 2886 - 2895.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. A. Wiley, A. Cerwenka, J. R. Harkema, R. W. Dutton, and A. G. Harmsen
Production of Interferon-{{gamma}} by Influenza Hemagglutinin-Specific CD8 Effector T Cells Influences the Development of Pulmonary Immunopathology
Am. J. Pathol., January 1, 2001; 158(1): 119 - 130.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Vizler, N. Bercovici, A. Heurtier, N. Pardigon, K. Goude, K. Bailly, C. Combadiere, and R. S. Liblau
Relative Diabetogenic Properties of Islet-Specific Tc1 and Tc2 Cells in Immunocompetent Hosts
J. Immunol., December 1, 2000; 165(11): 6314 - 6321.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Vukmanovic-Stejic, B. Vyas, P. Gorak-Stolinska, A. Noble, and D. M. Kemeny
Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes
Blood, January 1, 2000; 95(1): 231 - 240.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. S. N. Lamouse-Smith, D. S. Dougall, and S. A. McCarthy
Cytokine Requirements for Production of a Novel Anti-CD8-Resistant CTL Population
J. Immunol., October 15, 1999; 163(8): 4160 - 4167.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. C. Biedermann and J. S. Pober
Human Vascular Endothelial Cells Favor Clonal Expansion of Unusual Alloreactive CTL
J. Immunol., June 15, 1999; 162(12): 7022 - 7030.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, A. H. Sharpe, and D. A. Vallera
Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells
J. Immunol., June 1, 1999; 162(11): 6368 - 6377.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, and R. W. Dutton
Therapeutic Effects of Tumor-Reactive Type 1 and Type 2 CD8+ T Cell Subpopulations in Established Pulmonary Metastases
J. Immunol., June 1, 1999; 162(11): 6671 - 6680.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Tsukada, T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation
Blood, April 15, 1999; 93(8): 2738 - 2747.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
D. Zeng, D. Lewis, S. Dejbakhsh-Jones, F. Lan, M. Garcia-Ojeda, R. Sibley, and S. Strober
Bone Marrow NK1.1- and NK1.1+ T Cells Reciprocally Regulate Acute Graft versus Host Disease
J. Exp. Med., April 5, 1999; 189(7): 1073 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Chen, C. Thoburn, and A. D. Hess
Characterization of the Pathogenic Autoreactive T Cells in Cyclosporine-Induced Syngeneic Graft-Versus-Host Disease
J. Immunol., December 15, 1998; 161(12): 7040 - 7046.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. J. Martin, Y. Akatsuka, M. Hahne, and G. Sale
Involvement of Donor T-Cell Cytotoxic Effector Mechanisms in Preventing Allogeneic Marrow Graft Rejection
Blood, September 15, 1998; 92(6): 2177 - 2181.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Chen, G. S. Chatta, W. D. Rubin, J. G. Clark, R. C. Hackman, D. K. Madtes, D. H. Ligitt, Y. Kusunoki, P. J. Martin, and M. A. Cheever
T Cells Specific for a Polymorphic Segment of CD45 Induce Graft-Versus-Host Disease with Predominant Pulmonary Vasculitis
J. Immunol., July 15, 1998; 161(2): 909 - 918.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Cerwenka, L. L. Carter, J. B. Reome, S. L. Swain, and R. W. Dutton
In Vivo Persistence of CD8 Polarized T Cell Subsets Producing Type 1 or Type 2 Cytokines
J. Immunol., July 1, 1998; 161(1): 97 - 105.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, and D. A. Vallera
Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines
J. Immunol., June 1, 1998; 160(11): 5355 - 5365.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. H. Fowler, B. Whitfield, M. Livingston, P. Chrobak, and R. E. Gress
Non-Host-Reactive Donor CD8+ T Cells of Tc2 Phenotype Potently Inhibit Marrow Graft Rejection
Blood, June 1, 1998; 91(11): 4045 - 4050.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. P. Alyea, R. J. Soiffer, C. Canning, D. Neuberg, R. Schlossman, C. Pickett, H. Collins, Y. Wang, K. C. Anderson, and J. Ritz
Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant
Blood, May 15, 1998; 91(10): 3671 - 3680.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Halverson, G. N. Schwartz, C. Carter, R. E. Gress, and D. H. Fowler
In Vitro Generation of Allospecific Human CD8+ T Cells of Tc1 and Tc2 Phenotype
Blood, September 1, 1997; 90(5): 2089 - 2096.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.